Soluble interleukin-2 receptor serum level as a predictor of locoregional control and survival for patients with head and neck carcinoma

Tartour, Éric; Deneux, Laurent; Mosseri, Véronique; Jaulerry, C; Brunin, F.; Point, D; Validire, Pierre; Dubray, Bernard; Fridman, Wolf Herman; Rodriguez, José

doi:10.1002/(sici)1097-0142(19970401)79:7<1401::aid-cncr18>3.0.co;2-3

Cited by 28 publications

(12 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…This experience is in accordance with previous reports linking elevated IL-6 levels to extensive disease [20], and more specifically, to lymph node involvement [26]. It is not surprising since this multifunctional cytokine plays an important role in promoting tumorigenesis.…”

Section: Discussionsupporting

confidence: 92%

The prognostic value of the hypoxia markers CA IX and GLUT 1 and the cytokines VEGF and IL 6 in head and neck squamous cell carcinoma treated by radiotherapy ± chemotherapy

Schutter¹,

Landuyt²,

Verbeken³

et al. 2005

BMC Cancer

110

View full text Add to dashboard Cite

show abstract

Section: Discussionsupporting

confidence: 92%

The prognostic value of the hypoxia markers CA IX and GLUT 1 and the cytokines VEGF and IL 6 in head and neck squamous cell carcinoma treated by radiotherapy ± chemotherapy

Schutter¹,

Landuyt²,

Verbeken³

et al. 2005

BMC Cancer

110

View full text Add to dashboard Cite

show abstract

“…[8], [38], [39], [40] However, few studies have investigated the role of CRP in PLC. (Table S1) [38], [41], [42], [43], [44] The current study, which includes the largest number of patients, demonstrated that an elevated CRP level was associated with clinical tumor status (P = 0.005), clinical nodal status (P = 0.003) and differentiation of tumor cells (P = 0.014) in PLC, which is similar to previous findings with OSCC. [8].…”

Section: Discussionsupporting

confidence: 87%

Pre-Treatment Levels of C-Reactive Protein and Squamous Cell Carcinoma Antigen for Predicting the Aggressiveness of Pharyngolaryngeal Carcinoma

et al. 2013

View full text Add to dashboard Cite

The levels of squamous cell carcinoma antigen (SCC-Ag) and C-reactive protein (CRP) can be used to predict tumor invasion, lymph node metastasis, staging and survival in patients with oral cavity cancer. The present study analyzed the relationship between pre-treatment levels of SCC-Ag and CRP in relation to clinicopathological factors in patients with pharyngolaryngeal cancer (PLC) and determined whether elevated levels of CRP and SCC-Ag were associated with tumor metabolic activity via [18F] fluorodeoxyglucose positron emission tomography (FDG-PET). We retrospectively recruited one hundred and six PLC patients between June 2008 and December 2011. All patients received computed tomography (CT)/magnetic resonance imaging (MRI) and FDG-PET staging analyses, and the serum levels of SCC-Ag and CRP in these patients were measured prior to treatment. A SCC-Ag level ≥2.0 ng/ml and a CRP level ≥5.0 mg/L were significantly associated with clinical stage (P<0.001), clinical tumor status (P<0.001), and clinical nodal status (P<0.001). The elevation of both SCC-Ag and CRP levels was correlated with the standardized uptake value (SUV) max of the tumor (≥8.6 mg/L) and lymph nodes (≥5.7 ng/ml) (P = 0.019). The present study demonstrated that the presence of high levels of both pre-treatment SCC-Ag and CRP acts as a predictor of clinical stage, clinical tumor status, and clinical nodal status in patients with PLC. Moreover, elevated levels of SCC-Ag and CRP were associated with a high metabolic rate as well as the proliferative activity measured according to the SUVmax of the tumor and lymph nodes. Therefore, elevated levels of these two factors have the potential to serve as biomarkers for the prediction of tumor aggressiveness in cases of PLC.

show abstract

“…Although women generally live longer than men,38 there were no sex effects for recurrence or survival. Two‐year recurrence and survival rates were similar to those found in other studies 39, 40. The median serum IL‐6 level of the sample was 13 pg/mL (range, 0 pg/mL‐453 pg/mL), which was lower than the mean of 19.5 pg/mL (range, 0 pg/mL ‐313 pg/mL) found in a smaller sample (N = 90) of HNSCC patients 7.…”

Section: Discussionsupporting

confidence: 85%

Interleukin‐6 predicts recurrence and survival among head and neck cancer patients

Duffy

Taylor

Terrell

et al. 2008

Cancer

286

271

View full text Add to dashboard Cite

BACKGROUND. Increased pretreatment serum interleukin (IL)‐6 levels among patients with head and neck squamous cell carcinoma (HNSCC) have been shown to correlate with poor prognosis, but sample sizes in prior studies have been small and thus unable to control for other known prognostic variables. METHODS. A longitudinal, prospective cohort study determined the correlation between pretreatment serum IL‐6 levels, and tumor recurrence and all‐cause survival in a large population (N = 444) of previously untreated HNSCC patients. Control variables included age, sex, smoking, cancer site and stage, and comorbidities. Kaplan‐Meier plots and univariate and multivariate Cox proportional hazards models were used to study the association between IL‐6 levels, control variables, and time to recurrence and survival. RESULTS. The median serum IL‐6 level was 13 pg/mL (range, 0‐453). The 2‐year recurrence rate was 35.2% (standard error, 2.67%). The 2‐year death rate was 26.5% (standard error, 2.26%). Multivariate analyses showed that serum IL‐6 levels independently predicted recurrence at significant levels [hazard ratio (HR) = 1.32; 95% confidence interval (CI), 1.11 to 1.58; P = .002] as did cancer site (oral/sinus). Serum IL‐6 level was also a significant independent predictor of poor survival (HR = 1.22; 95% CI, 1.02 to 1.46; P = .03), as were older age, smoking, cancer site (oral/sinus), higher cancer stage, and comorbidities. CONCLUSIONS. Pretreatment serum IL‐6 could be a valuable biomarker for predicting recurrence and overall survival among HNSCC patients. Using IL‐6 as a biomarker for recurrence and survival may allow for earlier identification and treatment of disease relapse. Cancer 2008. © 2008 American Cancer Society.

show abstract

Soluble interleukin-2 receptor serum level as a predictor of locoregional control and survival for patients with head and neck carcinoma

Abstract: This study shows that serum s-IL-2-R level at the time of diagnosis represents a new independent prognostic variable for predicting the risk of locoregional recurrence and survival for patients with head and neck squamous cell carcinoma.

Cited by 28 publications

References 30 publications

The prognostic value of the hypoxia markers CA IX and GLUT 1 and the cytokines VEGF and IL 6 in head and neck squamous cell carcinoma treated by radiotherapy ± chemotherapy

The prognostic value of the hypoxia markers CA IX and GLUT 1 and the cytokines VEGF and IL 6 in head and neck squamous cell carcinoma treated by radiotherapy ± chemotherapy

Pre-Treatment Levels of C-Reactive Protein and Squamous Cell Carcinoma Antigen for Predicting the Aggressiveness of Pharyngolaryngeal Carcinoma

Interleukin‐6 predicts recurrence and survival among head and neck cancer patients

Contact Info

Product

Resources

About